home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

3-hr Virtual Seminar: South Korea - Navigating the South Korean Regulatory Compliance and Clinical Trial Environment

 
  October 30, 2012  
     
 
ComplianceOnline, Online Event
2012-11-09


Why Should You Attend:

This 3-hr session will help you gain a understanding of the regulatory structure, clinical trial requirements and the conduct of running clinical research in South Korea. It will prepare you for the regulatory approval processes, Agency meetings, the complexities of running studies in South Korea, the importance of partner selection and the cultural knowledge needed for success. The recent changes made by KFDA to be more sponsor-friendly will be reviewed. Real world experiences on actual interactions with the Agency since the changes, will also be discussed.

Areas Covered in the Seminar:

Part I: South Korea Regulatory Compliance

  • Overview of South Korea’s Healthcare System.
  • South Korean Drug Development Process.
  • Agency Review Process for Decision-Making.
  • Country Establishment Licensing & Procedures.
  • Requirements for Conducting Clinical Research.
  • South Korea and ICH (International Conference on Harmonization).
  • South Korea’s Desire for Innovative Products.
  • How South Korea Wants to be Involved in Clinical Trials.
  • The Changing KFDA.
  • Conducting Meetings with the Agency.
  • Korean Philosophy in Risk Evaluation.
  • How to Apply for Clinical Trials in South Korea; the CTA.
  • Amending the CTA.

Part II: Conducting Clinical Studies in South Korea

  • Likely Parameters Defining Clinical Trials; What to Anticipate.
  • Clinical Trial Start-Up; ICH GCP and GMP Requirements.
  • Importing the IMP & Supplies into South Korea.
  • Product Labeling Requirements.
  • Finding & Hiring CROs in South Korea.
  • Conducting Clinical Trials in South Korea.
  • Priority Reviews in South Korea.
  • Clinical Trial Pharmacovigilance Reporting.
  • CT Close-out and Reporting Requirements.
  • Cultural Aspects – Working in South Korea.
  • Effectively Working with the Regulators.
  • Do’s and Don’ts, Practical Experiences Shared.

Who Will Benefit:

This course will be beneficial to the following personnel in Pharmaceuticals, Medical Devices, and Combination Products manufacturing companies:

  • Clinical Trial/ Research Professionals
  • Regulatory Affairs Professionals
  • QA/ QC
  • Manufacturing/ Production
  • Global Business Development
  • Senior Management
 
 
Organized by: Complianceonline
Invited Speakers:

Robert J. Russell, (Bob) is the President of RJR Consulting, Inc. RJR Consulting Inc. specializes in understanding global regulatory issues for the pharmaceutical industry. Bob has more than 25 years of experience working with FDA and the Commission on technical issues as they relate to policy development, regulation, clinical trial and the medical device development process.

Prior to entering the consulting field, Mr. Russell was the Global Director of Regulatory Affairs for two Fortune 100 firms. These companies were major raw material suppliers to the pharmaceutical and medical device industry and one a joint-venture parent of a major pharmaceutical division.


 
Deadline for Abstracts: 2012-11-08
 
Registration:

For Registration:

http://www.complianceonline.com/ecommerce/control/trainingFocus/~product_id=702153?channel=hummolgen 

E-mail: referral@complianceonline.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.